PhaseBio Pharmaceuticals (PHAS) Financials

$0.04

$0.00 (5.26%)

As on 04-Jan-2023 09:30EDT

Market cap

$4 Mln

Revenue (TTM)

$-10 Mln

P/E Ratio

--

P/B Ratio

26.2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	-10.00	0.01	0.32	2.36	0.67	--
Cost of Revenue	--	--	--	--	15.46	6.21
Gross Profit	0.54	--	0.00	2.36	-14.79	-6.21
Operating Expenses	-13.05	0.12	85.18	42.10	20.31	8.54
Operating Profit (EBIT)	-104.20	-107.36	-84.86	-39.74	-19.64	-8.54
Other Income	-3.35	--	-13.71	0.49	-4.20	--
Profit before Tax	26.50	-0.13	-98.57	-39.25	-23.85	-10.25
Provision for Tax	-1.60	0.00	--	--	--	--
Profit after Tax (Net Income)	28.10	-0.13	-98.57	-39.25	-23.85	-10.25
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-102.84	-131.07	-98.57	-39.25	-23.85	-10.25

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	-117.40	-93.03	-25.20	59.98	50.93	-97.42
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	114.89	125.69	60.60	14.04	7.52	93.92
Current Liabilities	24.68	27.88	14.96	8.48	4.58	17.60
Total Liabilities	46.85	60.54	50.36	82.49	63.03	14.10

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	10.60	11.76	10.21	3.67	0.40	0.35
Current Assets	11.56	48.78	40.15	78.82	62.63	13.75
Total Assets	46.85	60.54	50.36	82.49	63.03	14.10
Total Debt*	5.37	7.85	12.13	14.70	7.50	16.38
Net Current Assets	-13.12	20.90	25.19	70.34	58.05	-3.85

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-47.42	-59.96	-39.59	-17.05	-8.26
Cash Flow from Investing Activities	--	-2.68	-1.41	-0.96	-0.12	-0.22
Cash from Financing Activities	--	63.77	15.47	53.53	64.80	18.17
Net Cash Inflow / Outflow	--	--	-45.90	12.97	47.63	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	0.27	-319.97	-58.97	210.91	12.18
ROE (%)	--	0.22	-566.86	-70.78	102.59	11.10
ROA (%)	34.34	-0.24	-148.38	-53.94	-61.84	-112.51
EBIT Margin (%)	-262.20	-1,204.12	-30,350.00	-1,616.73	-2,982.34	--
Net Margin (%)	-210.48	-1,210.15	736.16	-1,377.09	674.76	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	-196.75	-0.97	-0.86	2.53	--	--
EBIT Growth (%)	125.46	99.87	-154.43	-91.60	-134.76	10.41
Net Profit Growth (%)	125.19	99.87	-151.14	-64.59	-132.71	-11.14
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	--	--	--	--
Price / Book Value	26.18	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	0.00	-20.42	0.17	1.56	2.70	--
Close Price ($)	0.60	2.61	3.36	6.11	3.09	--
High Price ($)	4.10	5.83	8.49	16.65	6.00	--
Low Price ($)	0.50	1.83	2.60	2.56	2.55	--
Market Cap ($ Cr)	3.50	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	-0.08	-0.48	0.25	0.15	-0.17
Short term debt to equity ratio	-0.04	-0.06	-0.21	0.04	--	-0.12
Current Ratio	0.47	1.75	2.68	9.30	13.68	0.78
Quick Ratio	0.47	--	--	--	--	--
Interest Coverage	22.24	-137.72	-67.21	-35.47	-5.08	-3.12

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	17.81	52.22	34.88	--
Asset Turnover	-0.12	0.00	0.00	0.03	0.02	--
Receivable days	--	1,922.19	736.21	113.40	127.40	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	26.42	25.38
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.